- Telo Genomics (TSXV:TELO) has launched its cancer diagnostic platform TeloViewSMM to clinicians in the United States
- The platform performs six-factor quantitative analysis of 3D telomeres, which are the protective end caps of chromosomes
- TeloView also has the potential to characterize different cancers, identify their level of genomic instability and predict their progression
- Shares of Telo Genomics are up 8.70 per cent to C$0.25 as of 11:51 am ET
Telo Genomics (TSXV:TELO) has officially launched its TeloViewSMM cancer diagnostic platform to clinicians across the United States.
The launch will focus on testing for smoldering multiple myeloma (SMM), the precursor for multiple myeloma, which is a blood-based bone marrow cancer.
In a news release, the Toronto-based company said the platform performs six-factor quantitative analysis of 3D telomeres, the protective end caps of chromosomes.
Telo Genomics said the platform has the potential to characterize multiple cancers, identify their level of genomic instability and predict their progression.
“The commercial launch of our flagship TeloView platform is a major milestone for our company,” Telo Genomics’ CEO Kris Weinberg said in a statement. “We are also very active in discussions with platform partners and in the development of new tests in additional applications.”
The company said the test will be available for physicians to order under the SMART (smoldering multiple myeloma assessment of risk for transformation) protocol, which follows an industry trend in introducing novel molecular testing tools to gather information and feedback from clinicians.
The launch will first be done as a single-site CLIA (clinical laboratory improvement amendments) model but will also be done through commercial-scale delivery testing in partnership with large reference labs.
The TeloViewSMM platform has the potential to be a game changer for physicians in managing the care of patients diagnosed with smoldering multiple myeloma.
Telo Genomics is a clinical-stage company that has developed predictive and prognostic assay tools for oncology and neurological conditions.
Shares of Telo Genomics are up 8.70 per cent to C$0.25 as of 11:51 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Telo Genomics Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.